P/E ratio for Sorrento Therapeutics (SRNEQ)
P/E ratio as of May 2024 (TTM): -0.0268
According to Sorrento Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.0267857. At the end of 2022 the company had a P/E ratio of -0.6496.
P/E ratio history for Sorrento Therapeutics from 2007 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.6496 | -80.78% |
| 2021 | -3.38 | -39.32% |
| 2020 | -5.57 | 266.84% |
| 2019 | -1.52 | 10.41% |
| 2018 | -1.38 | -104.7% |
| 2017 | 29.2 | -821.82% |
| 2016 | -4.05 | -42.55% |
| 2015 | -7.05 | -7.26% |
| 2014 | -7.60 | 34.66% |
| 2013 | -5.64 | -40.74% |
| 2012 | -9.52 | -52.38% |
| 2011 | -20.0 | -66.67% |
| 2010 | -60.0 | -68.75% |
| 2009 | -192 | |
| 2007 | -35.7 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Karyopharm Therapeutics
KPTI | -0.7727 | 2,784.85% | 🇺🇸 USA |
 Exelixis EXEL | 76.2 | -284,613.75% | 🇺🇸 USA |
 Dicerna Pharmaceuticals DRNA | N/A | N/A | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.